Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03911141
Other study ID # 831230
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 12, 2019
Est. completion date January 27, 2024

Study information

Verified date February 2024
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to use a randomized, controlled trial to test the effectiveness of using gamification, financial incentives, or both to increase physical activity among patients with elevated risk for atherosclerotic cardiovascular disease (ASCVD). ASCVD is the leading cause of morbidity and mortality in the United States. Regular physical activity has been shown to reduce the risk of ASCVD, but less than 50% of US adults achieve enough physical activity to obtain these benefits.


Description:

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in the United States (US). Regular physical activity has been demonstrated to reduce the risk of ASCVD and is associated with a number of other health benefits. Yet, less than 50% of adults in the US achieve enough physical activity to actually obtain these benefits. Insights from behavioral economics have been shown to both better reflect the 'predictable irrationality' of humans and to be effective in designing interventions that achieve sustained improvements in health behavior. Our prior work has demonstrated that interventions using financial incentives and gamification can leverage principles from behavioral economics to increase physical activity during 3-month interventions and sustain effects in 3-month follow-up periods. These findings warrant further investigation of longer-term effects. In this study, we conduct a four-arm randomized, controlled trial to evaluate the effectiveness of using behavioral economic approaches including gamification, financial incentives, or both to increase physical activity among patients with elevated risk for atherosclerotic cardiovascular disease during a 12-month intervention with a 6-month follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 1062
Est. completion date January 27, 2024
Est. primary completion date July 24, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years or older - Have a 10-year ASCVD risk score of 7.5% or greater (including those with existing ASCVD) - Are able to provide informed consent Exclusion Criteria: - Are already participating in another physical activity study - An 18-month physical activity program is infeasible (e.g. metastatic cancer; unable to ambulate or provide informed consent) or unsafe (currently pregnant or told by a physician not to exercise) - They do not have a device (e.g. smartphone, tablet, or computer) to transmit data from the wearable activity tracker - Baseline step count is 7,500 or greater - They do not have a primary care physician in the University of Pennsylvania Health System.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Gamification
Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals. Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels. Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level. In the follow-up period, participants continue to get a daily text stating if they met their step goal.
Financial
Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets. During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day.

Locations

Country Name City State
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Proportion of weeks that achieve 150 minutes of MVPA during the 12 month intervention using a wearable device (Fitbit watch) to measure MVPA derived from step counts. Proportion of weeks that achieve at least 150 minutes of MVPA per week from baseline to the the intervention period. This will be measured using the Fitbit Charge 3 wearable device. Months 1-12
Other Proportion of weeks that achieve 150 minutes of MVPA during the 6 month follow-up using a wearable device (Fitbit watch) to measure MVPA derived from step counts. Proportion of weeks that achieve at least 150 minutes of MVPA per week from baseline to the follow-up period. This will be measured using the Fitbit Charge 3 wearable device. Months 1-18
Primary Change in mean daily step counts during the 12 month intervention using a wearable pedometer (Fitbit watch) to measure step count. Change in mean daily steps counts from baseline to the 12-month intervention period, excluding the 8-week ramp-up phase. This will be measured using the Fitbit Charge 3 wearable device. Months 1-12
Secondary Change in mean daily step counts during the 6 month follow-up using a wearable pedometer (Fitbit watch) to measure step count. Change in mean daily steps from baseline to the post-intervention follow-up period. This will be measured using the Fitbit Charge 3 wearable device. Months 1-18
Secondary Change in mean daily minutes of moderate to vigorous physical activity (MVPA) during the 12 month intervention using a wearable device (Fitbit watch) to measure MVPA derived from step counts. Change in mean daily minutes of MVPA from baseline to the intervention period, excluding the 8-week ramp up phase. This will be measured using the Fitbit Charge 3 wearable device. Months 1-12
Secondary Change in mean daily minutes of moderate to vigorous physical activity (MVPA) during the 6 month follow-up using a wearable device (Fitbit watch) to measure MVPA derived from step counts. Change in mean daily minutes of MVPA from baseline to the post-intervention follow-up period. This will be measured using the Fitbit Charge 3 wearable device. Months 1-18
See also
  Status Clinical Trial Phase
Recruiting NCT01572259 - Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism Phase 3
Completed NCT05792787 - Association Between Apical Periodontitis and Atherosclerotic Cardiovascular Diseases
Completed NCT03911284 - The Learning Registry
Recruiting NCT06048588 - YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis Phase 1/Phase 2
Active, not recruiting NCT03705234 - A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease Phase 3
Completed NCT03096288 - Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity Phase 4
Active, not recruiting NCT05485961 - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis Phase 2/Phase 3
Completed NCT01663402 - ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab Phase 3
Completed NCT03597412 - Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM Phase 4
Active, not recruiting NCT05974345 - In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Active, not recruiting NCT05030428 - Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease Phase 3
Completed NCT00185185 - Olmesartan Medoxomil in Atherosclerosis Phase 3
Completed NCT05129241 - Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
Completed NCT02991118 - Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Phase 3
Completed NCT05639244 - Time Restricted Eating and Innate Immunity N/A
Completed NCT02988115 - Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant Phase 3
Recruiting NCT04215237 - How Atorvastatin Affects the Gut Flora and Metabolomics? N/A
Completed NCT05355402 - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Phase 2
Recruiting NCT05726838 - The Belgian REAL (BE.REAL) Registry
Active, not recruiting NCT04462159 - The Young Heart Study N/A